Mitochondria as a therapeutic target in Alzheimer's disease and diabetes

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 6, 2009, Pages 492-511

  Moreira, Paula I ^a,b   Cardoso, Sandra M ^a,b   Pereira, Cláudia M ^a,b   Santos, Maria S ^a,c   Oliveira, Catarina R ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Alzheimer's disease; Antioxidants; Diabetes; Mitochondria; MitoQ; MitoVitE; SS peptides

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; CELECOXIB; CREATINE; DOCOSAHEXAENOIC ACID; DONEPEZIL; FOLIC ACID; GLYCEROPHOSPHORYLCHOLINE; INSULIN; LEVACECARNINE; MINOCYCLINE; PHOSPHATIDYLSERINE; PLACEBO; PYRIDOXINE; RIVASTIGMINE; S ADENOSYLMETHIONINE; THIOCTIC ACID; UBIDECARENONE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; CELL CYCLE; CELL DEATH; CLINICAL FEATURE; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; GLUCOSE METABOLISM; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MITOCHONDRION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; DIABETES MELLITUS; HUMANS; INSULIN; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MODELS, BIOLOGICAL; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 75849136180     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709789824651     Document Type: Review

References (276)

1. Ferri, C.P.; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; Jorm, A.; Mathers, C.; Menezes, P.R.; Rimmer, E.; Scazufca, M.; Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study Lancet, 2005, 366, 2112-2127.
2. Selkoe, D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature, 1999, 399, A23-A31.
3. Kalofoutis, C.; Piperi, C.; Kalofoutis, A.; Harris, F.; Phoenix, D.; Singh, J. Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. Exp. Clin. Cardiol., 2007, 12, 17-28.
4. Ross, S.A.; Gulve, E.A.; Wang, M. Chemistry and biochemistry of type 2 diabetes. Chem. Rev., 2004, 104, 1255-1282.
5. May, P.C.; Boggs, L.N.; Fuson, K.S. Neurotoxicity of human amylin in rat primary hippocampal cultures: similarity to Alzheimer's disease amyloid-beta neurotoxicity. J. Neurochem., 1993, 61, 2330-2333.
6. Tucker, H.M.; Rydel, R.E.; Wright, S.; Estus, S. Human amylin induces "apoptotic" pattern of gene expression concomitant with cortical neuronal apoptosis. J. Neurochem., 1998, 71, 506-516.
7. Lim, Y.A.; Ittner, L.M.; Lim, Y.L.; Götz, J. Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures. FEBS Lett., 2008, 582, 2188-2194.
8. Miklossy, J.; Qing, H.; Radenovic, A.; Kis, A.; Vileno, B.; Làszló, F.; Miller, L.; Martins, R.N.; Waeber, G.; Mooser, V.; Bosman, F.; Khalili, K.; Darbinian-Sarlissian, N.; McGeer, P.L. Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol. Aging, 2008, [Epub ahead of print].
9. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care, 2002, 25, 213-229.
10. Miles, W.R.; Root, H.F. Psychologic tests applied in diabetic patients. Arch. Intern. Med., 1922, 30, 767-777.
11. Weinger, K.; Jacobson, A.M. Cognitive impairment in patients with type 1 (insulin-dependent) diabetes mellitus. CNS Drugs, 1998, 9, 233-252.
12. Skoog, I.; Lernfelt, B.; Landahl, S.; Palmertz, B.; Andreasson, L.A.; Nilsson, L.; Persson, G.; Odén, A.; Svanborg, A. 15-year longitudinal study of blood pressure and dementia. Lancet, 1996, 347, 1141-1145.
13. Grant, W.B. Dietary links to Alzheimer's disease: 1999 update. J. Alzheimers Dis., 1999, 1, 197-201.
14. Gasparini, L.; Netzer, W.J.; Greengard, P.; Xu, H. Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol. Sci., 2002, 23, 288-293.
15. Craft, S.; Watson, G.S. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol., 2004, 3, 169-178.
16. Moreira, P.I.; Santos, M.S.; Seiça, R.; Oliveira, C.R. Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J. Neurol. Sci., 2007, 257, 206-214.
17. Hassing, L.B.; Dahl, A.K.; Thorvaldsson, V.; Berg, S.; Gatz, M.; Pedersen, N.L.; Johansson, B. Overweight in midlife and risk of dementia: a 40-year follow-up study. Int. J. Obes. (Lond)., 2009, [Epub ahead of print].
18. Buchanan, T.A. Pancreatic beta-cell loss and preservation in type 2 diabetes. Clin. Ther., 2003, 25, B32-B46.
19. Marchetti, P.; Dotta, F.; Lauro, D.; Purrello, F. An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. Regul. Pept., 2008, 146, 4-11.
20. Whitwell, J.L.; Jack, C.R. Jr.; Pankratz, V.S.; Parisi, J.E.; Knopman, D.S.; Boeve, B.F.; Petersen, R.C.; Dickson, D.W.; Josephs, K.A. Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease. Neuroimage, 2008, 39, 1034-1040.
21. Elias, P.K.; Elias, M.F.; D'Agostino, R.B.; Cupples, L.A.; Wilson, P.W.; Silbershatz, H.; Wolf, P.A. NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care, 1997, 20, 1388-1395.
22. Ott, A.; Stolk, R.P.; van Harskamp, F.; Pols, H.A.; Hofman, A.; Breteler, M.M. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology, 1999, 53, 1937-1942.
23. Gregg, E.W.; Yaffe, K.; Cauley, J.A.; Rolka, D.B.; Blackwell, T.L.; Narayan, K.M.; Cummings, S.R. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch. Intern. Med., 2000, 160, 174-180.
24. Ott, A.; Stolk, R.P.; Hofman, A.; van Harskamp, F.; Grobbee, D.E.; Breteler, M.M. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia, 1996, 39, 1392-1397.
25. Leibson, C.L.; Rocca, W.A.; Hanson, V.A.; Cha, R.; Kokmen, E.; O'Brien, P.C.; Palumbo, P.J. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am. J. Epidemiol., 1997, 145, 301-308.
26. Bruce, D,G.; Davis, W.A.; Casey, G.P.; Starkstein, S.E.; Clarnette, R.M.; Almeida, O.P.; Davis, T.M. Predictors of cognitive decline in older individuals with diabetes. Diabetes Care, 2008, 31, 2103-2107.
27. Zannis V.I.; Kardassis D.; Zanni, E.E. Genetic mutations affecting human lipoproteins, their receptors, and their enzymes, Adv. Hum. Genet., 1993, 21, 145-319.
28. Cedazo-Minguez, A.; Cowburn, R.F. Apolipoprotein E: a major piece in the Alzheimer's disease puzzle, J. Cell. Mol. Med., 2001, 5, 254-266.
29. Corder, E.H.; Saunders, A.M.; Strittmatter, W.J.; Schmechel, D.E.; Gaskell, P.C.; Small, G.W.; Roses, A.D.; Haines, J.L.; Pericak-Vance, M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 1993, 261, 921-923.
30. Blacker, D.; Haines, J.L.; Rodes, L.; Terwedow, H.; Go, R.C.; Harrell, L.E.; Perry, R.T.; Bassett, S.S.; Chase, G.; Meyers, D.; Albert, M.S.; Tanzi, R. ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology, 1997, 48, 139-147.
31. Peila, R.; Rodriguez, B.L.; Launer, L.J. Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes, 2002, 51, 1256-1262.
32. Alafuzoff, I.; Aho, L.; Helisalmi, S.; Mannermaa, A.; Soininen, H. Beta-amyloid deposition in brains of subjects with diabetes. Neuropathol. Appl. Neurobiol., 2009, 35, 60-68.
33. Akomolafe, A.; Beiser, A.; Meigs, J.B.; Au, R.; Green, R.C.; Farrer, L.A.; Wolf, P.A.; Seshadri, S. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch. Neurol., 2006, 63, 1551-1555.
34. Xu, W.; Qiu, C.; Winblad, B.; Fratiglioni, L. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes, 2007, 56, 211-216.
35. Janson, J.; Laedtke, T.; Parisi, J.E.; O'Brien, P.; Petersen, R.C.; Butler, P.C. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53, 474-481.
36. Kuusisto, J.; Koivisto, K.; Mykkanen, L.; Helkala, E.L.; Vanhanen, M.; Hanninen, T.; Kervinen, K.; Kesaniemi, Y.A.; Riekkinen, P.J.; Laakso, M. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ, 1997, 315, 1045-1049.
37. Luchsinger, J.A.; Tang, M.X.; Shea, S.; Mayeux, R. Hyperinsulinemia and risk of Alzheimer disease. Neurology, 2004, 63, 1187-1192.
38. Rönnemaa, E.; Zethelius, B.; Sundelöf, J.; Sundström, J.; Degerman-Gunnarsson, M.; Berne, C.; Lannfelt, L.; Kilander, L. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology, 2008, 71, 1065-1071.
39. Profenno, L.A.; Porsteinsson, A.P.; Faraone, S.V. meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol. Psychiatry, 2009, [Epub ahead of print].
40. Nielson, K.A.; Nolan, J.H.; Berchtold, N.C.; Sandman, C.A.; Mulnard, R.A.; Cotman, C.W. Apolipoprotein-E genotyping of diabetic dementia patients: is diabetes rare in Alzheimer's disease? J. Am. Geriatr. Soc., 1996, 44, 897-904.
41. Chui, H.C.; Mack, W.; Jackson, J.E.; Mungas, D., Reed, B.R.; Tinklenberg, J.; Chang, F.L.; Skinner, K.; Tasaki, C.; Jagust, W.J. Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch. Neurol., 2000, 57, 191-196.
42. Kalaria, R.N. The role of cerebral ischemia in Alzheimer's disease. Neurobiol. Aging, 2000, 21, 321-330.
43. Harris, M.I.; Flegal, K.M.; Cowie, C.C.; Eberhardt, M.S.; Goldstein, D.E.; Little, R.R.; Wiedmeyer, H.M.; Byrd-Holt, D.D. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care, 1998, 21, 518-524.
44. Levin, B.E. Metabolic sensors: viewing glucosensing neurons from a broader perspective. Physiol. Behav., 2002, 76, 397-401.
45. Mizuno, Y.; Oomura, Y. Glucose responding neurons in the nucleus tractus solitarius of the rat: in vitro study. Brain Res., 1984, 307, 109-116.
46. Kow, L.M.; Pfaff, D.W. Actions of feeding-relevant agents on hypothalamic glucose-responsive neurons in vitro. Brain Res. Bull., 1985, 15, 509-513.
47. Silver, I.A.; Erecińska, M. Extracellular glucose concentration in mammalian brain: continuous monitoring of changes during increased neuronal activity and upon limitation in oxygen supply in normo-, hypo-, and hyperglycemic animals. J. Neurosci., 1994, 14, 5068-5076.
48. Levin, B.E. Glucose-regulated dopamine release from substantia nigra neurons. Brain Res., 2000, 874, 158-164.
49. Horvath, T.L.; Andrews, Z.B.; Diano, S. Fuel utilization by hypothalamic neurons: roles for ROS. Trends Endocrinol. Metab., 2009, 20, 78-87.
50. Ashford, M.L.; Boden, P.R.; Treherne, J.M. Glucose-induced excitation of hypothalamic neurones is mediated by ATP-sensitive K+ channels. Pflugers Arch., 1990, 415, 479-483.
51. + channel in rat brain. Brain Res., 1998, 814, 41-54.
52. Yang, X.J.; Kow, L.M.; Funabashi, T.; Mobbs, C.V. Hypothalamic glucose sensor: similarities to and differences from pancreatic beta-cell mechanisms. Diabetes, 1999, 48, 1763-1772.
53. Rulifson, E.J.; Kim, S.K.; Nusse, R. Ablation of insulin-producing neurons in flies: growth and diabetic phenotypes. Science, 2002, 296, 1118-1120.
54. Tatar, M.; Bartke, A.; Antebi, A. The endocrine regulation of aging by insulin-like signals. Science, 2003, 299, 1346-1351.
55. Jolivalt, C.G.; Lee, C.A.; Beiswenger, K.K.; Smith, J.L.; Orlov, M.; Torrance, M.A.; Masliah, E. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J. Neurosci. Res., 2008, 86, 3265-3274.
56. Hong, M.; Lee, V.M. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J. Biol. Chem., 1997, 272, 19547-19553.
57. Mandelkow, E.M.; Drewes, G.; Biernat, J.; Gustke, N.; van Lint, J.; Vandenheede, J.R.; Mandelkow, E. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett., 1992, 314, 315-321.
58. Noble, W.; Planel, E.; Zehr, C.; Olm, V.; Meyerson, J.; Suleman, F.; Gaynor, K.; Wang, L.; LaFrancois, J.; Feinstein, B.; Burns, M.; Krishnamurthy, P.; Wen, Y.; Bhat, R.; Lewis, J.; Dickson, D.; Duff, K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. USA, 2005, 102, 6990-6995.
59. Flaherty, D.B.; Soria, J.P.; Tomasiewicz, H.G.; Wood, J.G. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. J. Neurosci. Res., 2000, 62, 463-472.
60. Schechter, R.; Beju, D.; Miller, K.E. The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. Biochem. Biophys. Res. Commun., 2005, 334, 979-986.
61. Clodfelder-Miller, B.J.; Zmijewska, A.A.; Johnson, G.V.; Jope, R.S. Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes, 2006, 55, 3320-3325.
62. Planel, E.; Tatebayashi, Y.; Miyasaka, T.; Liu, L.; Wang, L.; Herman, M.; Yu, W.H.; Luchsinger, J.A.; Wadzinski, B.; Duff, K.E.; Takashima, A. Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J. Neurosci., 2007, 27, 13635-13648.
63. Alessi, D.R.; Cohen, P. Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev., 1998, 8, 55-62.
64. Vanhaesebroeck, A.; Alessi, D.R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J., 2000, 346, 561-576.
65. Cross, D.A.; Alessi, D.R.; Cohen, P.; Andjelkovich, M.; Hemmings, B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature, 1995, 378, 785-789.
66. Phiel, C.J.; Wilson, C.A.; Lee, V.M.; Klein, P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature, 2003, 423, 435-439.
67. Solano, D.C.; Sironi, M.; Bonfini, C.; Solerte, S.B.; Govoni, S.; Racchi, M. Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J., 2000, 14, 1015-1022.
68. Gasparini, L.; Gouras, G.K.; Wang, R.; Gross, R.S.; Beal, M.F.; Greengard, P.; Xu, H. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci., 2001, 21, 2561-2570.
69. Hoyer, S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol., 2004, 490, 115-125.
70. Xie, L.; Helmerhorst, E.; Taddel, K.; Plewright, B.; van Bronswijk, W.; Martins, R. Alzheimer's β-amyloid peptides compete for insulin binding to the insulin receptor. J. Neurosci., 2002, 22, 1-5.
71. Lee, K.Y.; Koh, S.H.; Noh, M.Y.; Kim, S.H.; Lee, Y.J. Phosphatidylinositol-3-kinase activation blocks amyloid beta-induced neurotoxicity. Toxicology, 2008, 243, 43-50.
72. Wallace, W.C.; Akar, C.A.; Lyons, W.E. Amyloid precursor protein potentiates the neurotrophic activity of NGF. Mol. Brain Res., 1997, 52, 201-212.
73. Wallace, W.C.; Akar, C.A.; Lyons, W.E.; Kole, H.K.; Egan, J.E.; Wolozin, B. Amyloid precursor protein requires the insulin signalling pathway for neurotrophic activity. Mol. Brain Res., 1997, 52, 213-227.
74. Luo, J.J.; Wallace, M.S.; Hawver, D.B.; Kusiak, J.W.; Wallace, W.C. Characterization of the neurotrophic interaction between nerve growth factor and secreted alpha-amyloid precursor protein. J. Neurosci. Res., 2001, 63, 410-420.
75. Authier, F.; Posner, B.I.; Bergeron, J.J. Insulin-degrading enzyme. Clin. Invest. Med., 1996, 19, 149-160.
76. Bennett, R.G.; Hamel, F.G.; Duckworth, W.C. An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes, 2003, 52, 2315-2320.
77. Kurochkin, I.V.; Goto, S. Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett., 1994, 345, 33-37.
78. McDermott, J.R.; Gibson, A.M. Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem. Res., 1997, 22, 49-56.
79. Qiu, W.Q.; Walsh, D.M., Ye, Z.; Vekrellis, K.; Zhang, J.; Podlisny, M.B.; Rosner, M.R.; Safavi, A.; Hersh, L.B.; Selkoe, D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem., 1998, 273, 32730-32738.
80. Song, E.S.; Hersh, L.B. Insulysin: an allosteric enzyme as a target for Alzheimer's disease. J. Mol. Neurosci., 2005, 25, 201-206.
81. Farris, W.; Mansourian, S.; Chang, Y.; Lindsley, L.; Eckman, E.A.; Frosch, M.P.; Eckman, C.B.; Tanzi, R.E.; Selkoe, D.J.; Guenette, S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. USA, 2003, 100, 4162-4167.
82. Vekrellis, K.; Ye, Z.; Qiu, W.Q.; Walsh, D.; Hartley, D.; Chesneau, V.; Rosner, M.R.; Selkoe, D.J. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J. Neurosci., 2000, 20, 1657-1665.
83. Edbauer, D.; Willem, M.; Lammich, S.; Steiner, H.; Haass, C. Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD). J. Biol. Chem., 2002, 277, 13389-13393.
84. Perez, A.; Morelli, L.; Cresto, J.C.; Castano, E.M. Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem. Res., 2000, 25, 247-255.
85. Cook, D.G.; Leverenz, J.B.; McMillan, P.J.; Kulstad, J.J.; Ericksen, S.; Roth, R.A.; Schellenberg, G.D.; Jin, L.W.; Kovacina, K.S.; Craft, S. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am. J. Pathol., 2003, 162, 313-319.
86. Ho, L.; Qin, W.; Pompl, P.N.; Xiang, Z.; Wang, J., Zhao, Z.; Peng, Y.; Cambareri, G.; Rocher, A.; Mobbs, C.V.; Hof, P.R.; Pasinetti, G.M. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J., 2004, 18, 902-904.
87. Morelli, L.; Llovera, R.E.; Mathov, I.; Lue, L.F.; Frangione, B.; Ghiso, J.; Castano, E.M. Insulin-degrading enzyme in brain microvessels: proteolysis of amyloid {beta} vasculotropic variants and reduced activity in cerebral amyloid angiopathy. J. Biol. Chem., 2004, 279, 56004-56013.
88. Caccamo, A.; Oddo, S.; Sugarman, M.C.; Akbari, Y.; LaFerla, F.M. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol. Aging, 2005, 26, 645-654.
89. Wang, R.; Wang, S.; Malter, J.S.; Wang, D.S. Effects of 4-hydroxynonenal and amyloid-beta on expression and activity of endothelin converting enzyme and insulin degrading enzyme in SH-SY5Y cells. J. Alzheimers Dis., 2009, [Epub ahead of print].
90. Zhao, W.Q.; Lacor, P.N.; Chen, H., Lambert, M.P.; Quon, M.J.; Krafft, G.A.; Klein, W.L. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric Abeta. J. Biol. Chem., 2009, 284, 18742-18753.
91. Havrankova, J.; Roth, J.; Brownstein, M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature, 1978, 272, 827-829.
92. Havrankova, J.; Schmechel, D.; Roth, J.; Brownstein, M. Identification of insulin in rat brain. Proc. Natl. Acad. Sci. USA, 1978, 75, 5737-5741.
93. Baskin, D.G.; Figlewicz, D.P.; Woods, S.C.; Porte, D.; Jr.; Dorsa, D.M. Insulin in the brain. Annu. Rev. Physiol., 1987, 49, 335-347.
94. Unger, J.W.; Livingston, J.N.; Moss, A.M. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog. Neurobiol., 1991, 36, 343-362.
95. Bruning, J.C.; Gautam, D.; Burks, D.J.; Gillette, J.; Schubert, M.; Orban, P.C.; Klein, R.; Krone, W.; Muller-Wieland, D.; Kahn, C.R. Role of brain insulin receptor in control of body weight and reproduction. Science, 2000, 289, 2122-2125.
96. Schulingkamp, R.J.; Pagano, T.C.; Hung, D.; Raffa, R.B. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci. Biobehav. Rev., 2000, 24, 855-872.
97. Magistretti, P.J. Brain Energy Metabolism. In: Fundamental Neuroscience; Squire, L.R.; Bloom, F.E.; McConnell, S.K.; Roberts, J.L.; Spitzer, N.C.; Zigmond, M.J., Eds.; Academic Press: San Diego, 2003, pp. 339-360.
98. Baura, G.D.; Foster, D.M.; Porte, D.; Jr.; Kahn, S.E.; Bergman, R.N.; Cobelli, C.; Schwartz, M.W. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo: a mechanism for regulated insulin delivery to the brain. J. Clin. Invest., 1993, 92, 1824-1830.
99. Banks, W.A.; Jaspan, J.B.; Huang, W.; Kastin, A.J. Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides, 1997, 18, 1423-1429.
100. Pellerin, L.; Magistretti, P.J. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc. Natl. Acad. Sci. USA, 1994, 91, 10625-10629.
101. Schulingkamp, R.J.; Pagano, T.C.; Hung, D.; Raffa, R.B. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci. Biobehav. Rev., 2000, 24, 855-872.
102. Reagan, L.P.; Gorovits, N.; Hoskin, E.K.; Alves, S.E.; Katz, E.B.; Grillo, C.A.; Piroli, G.G.; McEwen, B.S.; Charron, M.J. Localization and regulation of GLUTx1 glucose transporter in the hippocampus of streptozotocin diabetic rats. Proc. Natl. Acad. Sci. USA, 2001, 98, 2820-2825.
103. Brant, A.M.; Jess, T.J.; Milligan, G.; Brown, C.M.; Gould, G.W. Immunological analysis of glucose transporters expressed in different regions of the rat brain and central nervous system. Biochem. Biophys. Res. Commun., 1993, 192, 1297-1302.
104. El Messari, S.; Leloup, C.; Quignon, M.; Brisorgueil, M.J.; Penicaud, L.; Arluison, M. Immunocytochemical localization of the insulin-responsive glucose transporter 4 (GLUT4) in the rat central nervous system. J. Comp. Neurol., 1998, 399, 492-512.
105. Apelt, J.; Mehlhorn, G.; Schliebs, R. Insulin-sensitive GLUT4 glucose transporters are colocalized with GLUT3-expressing cells and demonstrate a chemically distinct neuron-specific localization in rat brain. J. Neurosci. Res., 1999, 57, 693-705.
106. Ibberson, M.; Uldry, M.; Thorens, B. GLUTX1, a novel mammalian glucose transporter expressed in the central nervous system and insulin-sensitive tissues. J. Biol. Chem., 2000, 275, 4607-4612.
107. Vannucci, S.J.; Koehler-Stec, E.M.; Li, K.; Reynolds, T.H.; Clark, R.; Simpson, I.A. GLUT4 glucose transporter expression in rodent brain: effect of diabetes. Brain Res., 1998, 797, 1-11.
108. Badr, G.A.; Tang, J.; Ismail-Beigi, F.; Kern, T.S. Diabetes downregulates GLUT1 expression in the retina and its microvessels but not in the cerebral cortex or its microvessels. Diabetes, 2000, 49, 1016-1021.
109. Gjedde, A.; Crone, C. Blood-brain glucose transfer: repression in chronic hyperglycemia. Science, 1981, 214, 456-457.
110. Cornford, E.M.; Hyman, S.; Cornford, M.E.; Clare-Salzler, M. Down-regulation of blood-brain glucose transport in the hyperglycemic nonobese diabetic mouse. Neurochem. Res., 1995, 20, 869-873.
111. Blass, J.P.; Gibson, G.E. Cerebrometabolic aspects of delirium in relationship to dementia. Dement. Geriatr. Cogn. Disord., 1999, 10, 335-338.
112. Blass, J.P.; Sheu, R.K.; Gibson, G.E. Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise. Ann. N. Y. Acad. Sci., 2000, 903, 204-221.
113. Azari, N.P.; Pettigrew, K.D.; Schapiro, M.B.; Haxby, J.V.; Grady, C.L.; Pietrini, P.; Salerno, J.A.; Heston, L.L.; Rapoport, S.I.; Horwitz, B. Early detection of Alzheimer's disease: a statistical approach using positron emission tomographic data. J. Cereb. Blood Flow Metab., 1993, 13, 438-447.
114. Pettegrew, J.W.; Panchalingam, K.; Klunk, W.E.; McClure, R.J.; Muenz, L.R. Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol. Aging, 1994, 15, 117-132.
115. Small, G.W.; Komo, S.; La Rue, A.; Saxena, S.; Phelps, M.E.; Mazziotta, J.C.; Saunders, A.M.; Haines, J.L.; Pericak-Vance, M.A.; Roses, A.D. Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Ann. NY Acad. Sci., 1996, 802, 70-78.
116. Fukuyama, H.; Ogawa, M.; Yamauchi, H.; Yamaguchi, S.; Kimura, J.; Yonekura, Y.; Konishi, J. Altered cerebral energy metabolism in Alzheimer's disease: a PET study. J. Nucl. Med., 1994, 35, 1-6.
117. Hoyer, S. Risk factors for Alzheimer's disease during aging. Impacts of glucose/energy metabolism. J. Neural Transm. Suppl., 1998, 54, 187-194.
118. Praprotnik, D.; Smith, M.A.; Richey, P.L.; Vinters, H.V.; Perry, G. Plasma membrane fragility in dystrophic neurites in senile plaques of Alzheimer's disease: an index of oxidative stress. Acta Neuropathol. (Berl.), 1996, 91, 1-5.
119. Praprotnik, D.; Smith, M.A.; Richey, P.L.; Vinters, H.V.; Perry, G. Filament heterogeneity within the dystrophic neurites of senile plaques suggests blockage of fast axonal transport in Alzheimer's disease. Acta Neuropathol. (Berl.), 1996, 91, 226-235.
120. Perry, G.; Smith, M.A.; McCann, C.E.; Siedlak, S.L.; Jones, P.K.; Friedland, R.P. Cerebrovascular muscle atrophy is a feature of Alzheimer's disease. Brain Res., 1998, 791, 63-66.
121. Perry, G.; Nunomura, A.; Raina, A.K,.; Aliev, G.; Siedlak, S.L.; Harris, P.L.; Casadesus, G.; Petersen, R.B.; Bligh-Glover, W.; Balraj, E.; Petot, G.J.; Smith, M.A. A metabolic basis for Alzheimer disease. Neurochem. Res., 2003, 28, 1549-1552.
122. Cash, A.D.; Aliev, G.; Siedlak, S.L.; Nunomura, A.; Fujioka, H.; Zhu, X.; Raina, A.K.; Vinters, H.V.; Tabaton, M.; Johnson, A.B.; Paula-Barbosa, M.; Avila, J.; Jones, P.K.; Castellani, R.J.; Smith, M.A.; Perry, G. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am. J. Pathol., 2003, 162, 1623-1627.
123. Kalaria, R.N.; Gravina, S.A.; Schmidley, J.W.; Perry, G.; Harik, S.I. The glucose transporter of the human brain and blood-brain barrier. Ann. Neurol., 1988, 24, 757-764.
124. Liu, Y.; Liu, F.; Iqbal, K.; Grundke-Iqbal, I.; Gong, C.X. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett., 2008, 582, 359-364.
125. Liu, F.; Shi, J.; Tanimukai, H.; Gu, J.; Gu, J.; Grundke-Iqbal, I.; Iqbal, K.; Gong, C.X. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain, 2009, 132, 1820-1832.
126. Nishimura, T.; Hashikawa, K.; Fukuyama, H.; Kubota, T.; Kitamura, S.; Matsuda, H.; Hanyu, H.; Nabatame, H.; Oku, N.; Tanabe, H.; Kuwabara, Y.; Jinnouchi, S.; Kubol, A. Decreased cerebral blood flow and prognosis of Alzheimer's disease: a multicenter HMPAO-SPECT study. Ann. Nucl. Med., 2007, 21, 15-23.
127. Obara, K.; Meyer, J.S.; Mortel, K.F.; Muramatsu, K. Cognitive declines correlate with decreased cortical volume and perfusion in dementia of Alzheimer type. J. Neurol. Sci., 1994, 127, 96-102.
128. Tiehuis, A.M.; van der Graaf, Y.; Visseren, F.L.; Vincken, K.L.; Biessels, G.J.; Appelman, A.P.; Kappelle, L.J.; Mali, W.P.; SMART Study Group. Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease. Stroke, 2008, 39, 1600-1603.
129. Saczynski, J.S.; Siggurdsson, S.; Jonsson, P.V.; Eiriksdottir, G.; Olafsdottir, E.; Kjartansson, O.; Harris, T.B.; van Buchem, M.A.; Gudnason, V.; Launer, L.J. Glycemic Status and Brain Injury in Older Persons: The Age Gene/Environment Susceptibility - Reykjavik Study. Diabetes Care, 2009, 32, 1608-1613.
130. Asil, T.; Utku, U.; Balci, K.; Uzunca, I. Changing cerebral blood flow velocity by transcranial Doppler during head up tilt in patients with diabetes mellitus. Clin. Neurol. Neurosurg., 2007, 109, 1-6.
131. Petrie, E.C.; Cross, D.J.; Galasko, D.; Schellenberg, G.D.; Raskind, M.A.; Peskind, E.R.; Minoshima, S. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch. Neurol., 2009, 66, 632-637.
132. Mosconi, L.; Mistur, R.; Switalski, R.; Tsui, W.H.; Glodzik, L.; Li, Y.; Pirraglia, E.; De Santi, S.; Reisberg, B.; Wisniewski, T.; de Leon, M.J. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36, 811-822.
133. Rönnemaa, E.; Zethelius, B.; Sundelöf, J.; Sundström, J.; Degerman-Gunnarsson, M.; Lannfelt, L.; Berne, C.; Kilander, L. Glucose metabolism and the risk of Alzheimer's disease and dementia: a population-based 12 year follow-up study in 71-year-old men. Diabetologia, 2009, 52, 1504-1510.
134. Sorbi, S.; Bird, E.D.; Blass, J.P. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann. Neurol., 1983, 13, 72-78.
135. Kish, S.J. Brain energy metabolizing enzymes in Alzheimer's disease: alpha-ketoglutarate dehydrogenase complex and cytochrome oxidase. Ann. NY Acad. Sci., 1997, 826, 218-228.
136. Gibson, G.E.; Park, L.C.; Sheu, K.F.; Blass, J.P.; Calingasan, N.Y. The alpha-ketoglutarate dehydrogenase complex in neurodegeneration. Neurochem. Int., 2000, 36, 97-112.
137. Bubber, P.; Haroutunian, V.; Fisch, G.; Blass, J.P.; Gibson, G.E. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol., 2005, 57, 695-703.
138. Tretter, L.; Adam-Vizi, V. Inhibition of Krebs cycle enzymes by hydrogen peroxide: a key role of α-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. J. Neurosci., 2000, 20, 8972-8979.
139. Perry, E.K.; Perry, R.H.; Tomlinson, B.E.; Blessed, G.; Gibson, P.H. Coenzyme A-acetylating enzymes in Alzheimer's disease: possible cholinergic 'compartment' of pyruvate dehydrogenase. Neurosci. Lett., 1980, 18, 105-110.
140. Mulder, M.; Ravid, R.; Swaab, D.F.; de Kloet, E.R.; Haasdijk, E.D.; Julk, J.; van der Boom, J.; Havekes, L.M. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis. Assoc. Disord., 1998, 12, 198-203.
141. Hoyer, S. Oxidative energy metabolism in Alzheimer brain. Studies in early-onset and late-onset cases. Mol. Chem. Neuropathol., 1992, 16, 207-224.
142. Parker, W.D.; Jr.; Mahr, N.J.; Filley, C.M.; Parks, J.K.; Hughes, D.; Young, D.A.; Cullum, C.M. Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology, 1994, 44, 1086-1090.
143. Cardoso, S.M.; Proença, M.T.; Santos, S.; Santana, I.; Oliveira, C.R. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol. Aging, 2004, 25, 105-110.
144. Kish, S.J.; Bergeron, C.; Rajput, A.; Dozic, S.; Mastrogiacomo, F.; Chang, L.J.; Wilson, J.M.; DiStefano, L.M.; Nobrega, J.N. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem., 1992, 59, 776-779.
145. Mutisya, E.M.; Bowling, A.C.; Beal, M.F. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem., 1994, 63, 2179-2184.
146. Chagnon, P.; Bétard, C.; Robitaille, Y.; Cholette, A.; Gauvreau, D. Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases. Neuroreport, 1995, 6, 711-715.
147. Castellani, R.; Hirai, K.; Aliev, G.; Drew, K.L.; Nunomura, A.; Takeda, A.; Cash, A.D.; Obrenovich, M.E.; Perry, G.; Smith, M.A. Role of mitochondrial dysfunction in Alzheimer's disease. J. Neurosci. Res., 2002, 70, 357-360.
148. King, M.P.; Attardi, G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science, 1989, 246, 500-503.
149. Davis, R.E.; Miller, S.; Hermstadt, C.; Ghosh, S.S.; Fahy, E.; Shinobu, L.A.; Galasko, D.; Thal, L.J.; Beal, M.F.; Howell, N.; Parker, W.D.; Jr. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 1997, 94, 4526-4531.
150. Swerdlow, R.H.; Parks, J.K.; Cassarino, D.S.; Maguire, D.J.; Maguire, R.S.; Bennett, J.P.; Jr.; Davis, R.E.; Parker, W.D.; Jr. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology, 1997, 49, 918-925.
151. Cardoso, S.M.; Santana, I.; Swerdlow, R.H.; Oliveira, C.R. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J. Neurochem., 2004, 89, 1417-1426.
152. Amacher, D.E. Drug-associated mitochondrial toxicity and its detection. Curr. Med. Chem., 2005, 12, 1829-1839.
153. Sas, K.; Robotka, H.; Toldi, J.; Vécsei, L. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J. Neurol. Sci., 2007, 257, 221-239.
154. Moreira, P.I.; Duarte, A.I.; Santos, M.S.; Rego, A.C.; Oliveira, C.R. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J. Alzheimers Dis., 2009, 16, 741-761.
155. Desco, M.C.; Asensi, M.; Marquez, R.; Martinez-Valls, J.; Vento, M.; Pallardo, F.V. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes, 2002, 51, 1118-1124.
156. Pan, H.Z.; Zhang, L.; Guo, M.Y.; Sui, H.; Li, H.; Wu, W.H.; Qu, N.Q.; Liang, M.H.; Chang, D. The oxidative stress status in diabetes mellitus and diabetic nephropathy. Acta Diabetol., 2009, [Epub ahead of print].
157. Baynes, J.W. Role of oxidative stress in development of complications in diabetes. Diabetes, 1991, 40, 405-412.
158. Reagan, L.P.; Magarinos, A.M.; Yee, D.K.; Swzeda, L.I.; Van Bueren, A.; McCall, A.L.; McEwen, B.S. Oxidative stress and HNE conjugation of GLUT3 are increased in the hippocampus of diabetic rats subjected to stress. Brain Res., 2000, 862, 292-300.
159. Zherebitskaya, E.; Akude, E.; Smith, D.R.; Fernyhough, P. Development of selective axonopathy in adult sensory neurons isolated from diabetic rats: role of glucose-induced oxidative stress. Diabetes, 2009, 58, 1356-1364.
160. Evans, J.L.; Goldfine, I.D.; Maddux, B.A.; Grodsky, G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev., 2002, 23, 599-622.
161. Maritim, A.C.; Sanders, R.A.; Watkins III, J.B. Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol., 2003, 17, 24-38.
162. Lim, S.C.; Tan, H.H.; Goh, S.K.; Subramaniam, T.; Sum, C.F.; Tan, I.K.; Lee, B.L.; Ong, C.N. Oxidative burden in prediabetic and diabetic individuals: evidence from plasma coenzyme Q(10). Diabet. Med., 2006, 23, 1344-1349.
163. Aragno, M.; Brignardello, E.; Tamagno, E.; Gatto, V.; Danni, O.; Boccuzzi, G. Dehydroepiandrosterone administration prevents the oxidative damage induced by acute hyperglycemia in rats. J. Endocrinol., 1997, 155, 233-240.
164. Schmeichel, A.M.; Schmelzer, J.D.; Low, P.A. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes, 2003, 52, 165-71.
165. Leinninger, G.M.; Backus, C.; Sastry, A.M.; Yi, Y.B.; Wang, C.W.; Feldman, E.L. Mitochondria in DRG neurons undergo hyperglycemic mediated injury through Bim, Bax and the fission protein Drp1. Neurobiol. Dis., 2006, 23, 11-22.
166. Yu, T.; Sheu, S.S.; Robotham, J.L.; Yoon, Y. Mitochondrial fission mediates high glucose-induced cell death through elevated production of reactive oxygen species. Cardiovasc. Res., 2008, 79, 341-351.
167. Moreira, P.I.; Santos, M.S.; Sena, C.; Seiça, R.; Oliveira, C.R. Insulin protects against amyloid β-peptide toxicity in brain mitochondria of diabetic rats. Neurobiol. Dis., 2005, 18, 628-637.
168. Beyer, R.E. The participation of coenzyme Q in free radical production and antioxidation. Free Radic. Biol. Med., 1990, 8, 545-565.
169. Ernster, L.; Dallner, G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta, 1995, 1271, 195-204.
170. Ebadi, M.; Muralikrishnan, D.; Pellett, L.J.; Murphy, T.; Drees, K. Ubiquinone (coenzyme Q10) and complex I in mitochondrial oxidative disorder of Parkinson's disease. Proc. West. Pharmacol. Soc., 2000, 43, 55-63.
171. Gerbitz, K.D.; Gempel, K.; Brdiczka, D. Mitochondria and diabetes. Genetic, biochemical, and clinical implications of the cellular energy circuit. Diabetes, 1996, 45, 113-126.
172. van den Ouweland, J.M.; Maechler, P.; Wollheim, C.B.; Attardi, G.; Maassen, J.A. Functional and morphological abnormalities of mitochondria harboring the tRNA (Leu) (UUR) mutation in mitochondrial DNA derived from patients with maternally inherited diabetes and deafness (MIDD) and progressive kidney disease. Diabetologia, 1999, 42, 485-492.
173. Hollenbeck, C.B.; Reaven, G.M. Treatment of patients with non-insulin dependent diabetes mellitus: diabetic control and insulin secretion and action after different treatment modalities. Diabet. Med., 1987, 4, 311-316.
174. Moreira, P.I.; Santos, M.S.; Moreno, A.M.; Seiça, R.; Oliveira, C.R. Increased vulnerability of brain mitochondria in diabetic (Goto-Kakizaki) rats with aging and amyloid-beta exposure. Diabetes, 2003, 52, 1449-1456.
175. Baydas, G.; Nedzvetskii, V.S.; Tuzcu, M.; Yasar, A.; Kirichenko, S.V. Increase of glial fibrillary acidic protein and S-100B in hippocampus and cortex of diabetic rats: effects of vitamin E. Eur. J. Pharmacol., 2003, 462, 67-71.
176. Staniszewska, M.M.; Nagaraj, R.H. Upregulation of glyoxalase fails to normalize methylglyoxal levels: a possible mechanism for biochemical changes in diabetic mouse lense. Mol. Cell Biochem., 2006, 288, 29-36.
177. Chen, F.; Wollmer, M.A.; Hoerndli, F.; Münch, G.; Kuhla, B.; Rogaev, E.I.; Tsolaki, M.; Papassotiropoulos, A.; Götz, J. Role for glyoxalase I in Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2004, 101, 7687-7692.
178. Takeuchi, M.; Yamagishi, S. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J. Alzheimers Dis., 2009, 16, 845-858.
179. 2+ disregulation in diabetes mellitus. Eur. J. Pharmacol., 2002, 447, 201-209.
180. Clapham, D.E. Calcium signaling. Cell, 1995, 80, 259-268.
181. Drögue, W. Free radicals in the physiological control of cell function. Physiol. Rev., 2002, 82, 47-95.
182. Javadov, S.; Karmazyn, M.; Escobales, N. Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. J. Pharmacol. Exp. Ther., 2009, 330, 670-678.
183. Khachaturian, Z.S. Calcium hypothesis of Alzheimer's disease and brain aging. Ann. NY Acad. Sci., 1994, 747, 1-11.
184. Kostyuk, E.; Voitenko, N.; Kruglikov, I.; Shmigol, A.; Shishkin, V.; Efimov, A.; Kostyuk, P. Diabetes-induced changes in calcium homeostasis and the effects of calcium channel blockers in rat and mice nociceptive neurons. Diabetologia, 2001, 44, 1302-1309.
185. Kalichman, M.W.; Powell, H.C.; Mizisin, A.P. Reactive, degenerative, and proliferative Schwann cell responses in experimental galactose and human diabetic neuropathy. Acta Neuropathol. (Berl.), 1998, 95, 47-56.
186. Sasaki, H.; Schmelzer, J.D.; Zollman, P.J.; Low, P.A. Neuropathology and blood flow of nerve, spinal roots and dorsal root ganglia in longstanding diabetic rats. Acta Neuropathol. (Berl.), 1997, 93, 118-128.
187. Nishikawa, T.; Edelstein, D.; Du, X.L.; Yamagishi, S.; Matsumura, T.; Kaneda, Y.; Yorek, M.A.; Beebe, D.; Oates, P.J.; Hammes, H.P.; Giardino, I.; Bronwlee, M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 2000, 404, 787-790.
188. Lustbader, J.W.; Cirilli, M.; Lin, C.; Xu, H.W.; Takuma, K.; Wang, N.; Caspersen, C.; Chen, X.; Pollak, S.; Chaney, M.; Trinchese, F.; Liu, S.; Gunn-Moore, F., Lue, L.F.; Walker, D.G.; Kuppusamy, P.; Zewier, Z.L.; Arancio, O.; Stern, D.; Yan, S.S.; Wu, H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science, 2004, 304, 448-452.
189. Takuma K, Yao J, Huang J, Xu H, Chen X, Luddy J, Trillat, A.C.; Stern, D.M.; Arancio, O.; Yan, S.S. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J., 2005, 19, 597-598.
190. Crouch, P.J.; Blake, R.; Duce, J.A.; Ciccotosto, G.D.; Li, Q.X.; Barnham, K.J.; Curtain, C.C.; Cherny, R.A.; Cappai, R.; Dyrks, T.; Masters, C.L.; Trounce, I.A. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-1-42. J. Neurosci., 2005, 25, 672-679.
191. Anandatheerthavarada, H.K.; Biswas, G.; Robin, M.A.; Avadhani, N.G. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J. Cell Biol., 2003, 161, 41-54.
192. Leissring, M.A.; Farris, W.; Wu, X.; Christodoulou, D.C.; Haigis, M.C.; Guarente, L.; Selkoe, D.J. Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem. J., 2004, 383, 439-446.
193. Hansson, C.A.; Frykman, S.; Farmery, M.R.; Tjernberg, L.O.; Nilsberth, C; Pursglove, S.E.; Ito, A.; Winblad, B.; Cowburn, R.F.; Thyberg, J.; Ankarcrona, M. Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria. J. Biol. Chem., 2004, 279, 51654-51660.
194. Cardoso, S.M.; Santos, S.; Swerdlow, R.H.; Oliveira, C.R. Functional mitochondria are required for amyloid beta-mediated neurotoxicity. FASEB J., 2001, 15, 1439-1441.
195. Pereira, C.; Santos, M.S.; Oliveira, C. Mitochondrial function impairment induced by amyloid beta-peptide on PC12 cells. Neuroreport, 1998, 9, 1749-1755.
196. Pereira, C.; Santos, M.S.; Oliveira, C. Involvement of oxidative stress on the impairment of energy metabolism induced by Abeta peptides on PC12 cells: protection by antioxidants. Neurobiol. Dis., 1999, 6, 209-219.
197. Keil, U.; Bonert, A.; Marques, C.A.; Scherping, I.; Weyermann, J.; Strosznajder, J.B.; Müller-Spahn, F.; Haass, C.; Czech, C.; Pradier, L.; Müller, W.E.; Eckert, A. Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J. Biol. Chem., 2004, 279, 50310-50320.
198. David, D.C.; Hauptmann, S.; Scherping, I.; Schuessel, K.; Keil, U.; Rizzu, P.; Ravid, R.; Dröse, S.; Brandt, U.; Müller, W.E.; Eckert, A.; Götz, J. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem., 2005, 280, 23802-23814.
199. Eckert, A.; Hauptmann, S.; Scherping, I.; Meinhardt, J.; Rhein, V.; Dröse, S.; Brandt, U.; Fändrich, M.; Müller, W.E.; Götz, J. Oligomeric and fibrillar species of beta-amyloid (Abeta42) both impair mitochondrial function in P301L tau transgenic mice. J. Mol. Med., 2008, 86, 1255-1267.
200. Moreira, P.I.; Santos, M.S.; Sena, C.; Nunes, E.; Seiça, R.; Oliveira, C.R. CoQ10 therapy attenuates amyloid beta-peptide toxicity in brain mitochondria isolated from aged diabetic rats. Exp. Neurol., 2005, 196, 112-119.
201. Moreira, P.I.; Santos, M.S.; Moreno, A.; Oliveira, C. Amyloid beta-peptide promotes permeability transition pore in brain mitochondria. Biosci. Rep., 2001, 21, 789-800.
202. Moreira, P.I.; Santos, M.S.; Moreno, A.; Rego, A.C.; Oliveira, C. Effect of amyloid beta-peptide on permeability transition pore: a comparative study. J. Neurosci. Res., 2002, 69, 257-267.
203. Behl, C.; Davies, J.B.; Lesley, R.; Schubert, D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell, 1997, 77, 817-827.
204. Milton, N.G.N. Inhibition of catalase activity with 3-amino-triaz-ole enhances the cytotoxicity of the Alzheimer's amyloid-β peptide. Neurotoxicology, 2001, 22, 767-774.
205. Stump, C.S.; Short, K.R.; Bigelow, M.L.; Schimke, J.M.; Nair, K.S. Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts. Proc. Natl. Acad. Sci. USA, 2003, 100, 7996-8001.
206. Boirie, Y.; Short, K.R.; Ahlman, B.; Charlton, M.; Nair, K.S. Tissue-specific regulation of mitochondrial and cytoplasmic protein synthesis rates by insulin. Diabetes, 2001, 50, 2652-2658.
207. Gustafsson, H.; Soderdahl, T.; Jonsson, G.; Bratteng, J.O.; Forsby, A. Insulin-like growth factor type 1 prevents hyperglycemia-induced uncoupling protein 3 down-regulation and oxidative stress. J. Neurosci. Res., 2004, 77, 285-291.
208. Huang, T.J.; Price, S.A.; Chilton, L.; Calcutt, N.A.; Tomlinson, D.R.; Verkhratsky, A.; Fernyhough, P. Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. Diabetes, 2003, 52, 2129-2136.
209. Li, Y.; Wu, H.; Khardori, R.; Song, Y.H.; Lu, Y.W.; Geng, Y.J. Insulin-like growth factor-1 receptor activation prevents high glucose-induced mitochondrial dysfunction, cytochrome-c release and apoptosis. Biochem. Biophys. Res. Commun., 2009, 384, 259-264.
210. Hong, F.; Kwon, S.J.; Jhun, B.S.; Kim, S.S.; Ha, J.; Kim, S.J.; Sohn, N.W.; Kang, C.; Kang, I. Insulin-like growth factor-1 protects H9c2 cardiac myoblasts from oxidative stress-induced apoptosis via phosphatidylinositol 3-kinase and extracellular signal-regulated kinase pathways. Life Sci., 2001, 68, 1095-1105.
211. Napier, J.R.; Thomas, M.F.; Sharma, M.; Hodgkinson, S.C.; Blass, J.J. Insulin-like growth factor-I protects myoblasts from apoptosis but requires other factors to stimulate proliferation. J. Endocrinol., 1999, 163, 63-68.
212. Duarte, A.I.; Santos, M.S.; Oliveira, C.R.; Rego, A.C. Insulin neuroprotection against oxidative stress in cortical neurons - involvement of uric acid and glutathione antioxidant defenses. Free Radic. Biol. Med., 2005, 39, 876-889.
213. Duarte, A.I.; Santos, P.; Oliveira, C.R.; Santos, M.S.; Rego, A.C. Insulin neuroprotection against oxidative stress is mediated by Akt and GSK-3beta signaling pathways and changes in protein expression. Biochim. Biophys. Acta, 2008, 1783, 994-1002.
214. Niikura, T.; Hashimoto, Y.; Okamoto, T.; Abe, Y.; Yasukawa, T.; Kawasumi, M.; Hiraki, T.; Kita, Y.; Terashita, K.; Kouyama, K.; Nishimoto, I. Insulin-like growth factor I (IGF-I) protects cells from apoptosis by Alzheimer's V642I mutant amyloid precursor protein through IGF-I receptor in an IGF-binding protein-sensitive manner. J. Neurosci., 2001, 21, 1902-1910.
215. Rensink, A.A.M.; Otte-Höler, I.; de Boer, R.; Bosch, R.R.; ten Donkelaar, H.J.; de Waal, R.M.W.; Verbeek, M.M.; Kremer, B. Insulin inhibits amyloid β-induced cell death in cultured human brain pericytes. Neurobiol. Aging, 2004, 25, 93-103.
216. Pilatus; U.; Lais, C.; Rochmont, A.D.; Kratzsch, T.; Frölich, L.; Maurer, K.; Zanella, F.E.; Lanfermann, H.; Pantel, J. Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy. Psychiatry Res., 2009, 173, 1-7.
217. Andres, R.H.; Huber, A.W.; Schlattner, U.; Pérez-Bouza, A.; Krebs, S.H.; Seiler, R.W.; Wallimann, T.; Widmer, H.R. Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue. Neuroscience, 2005, 133, 701-713.
218. + toxicity in an organotypic tissue culture system. Cell Transplant., 2005, 14, 537-550.
219. Zhu, S.; Li, M.; Figueroa, B.E.; Liu, A.; Stavrovskaya, I.G.; Pasinelli, P.; Beal, M.F.; Brown, R.H.; Jr.; Kristal, B.S.; Ferrante, R.J.; Friedlander, R.M. Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. J. Neurosci., 2004, 24, 5909-5912.
220. Malcon, C.; Kaddurah-Daouk, R.; Beal, M.F. Neuroprotective effects of creatine administration against NMDA and malonate toxicity. Brain Res., 2000, 860, 195-198.
221. Sullivan, P.G.; Geiger, J.D.; Mattson, M.P.; Scheff, S.W. Dietary supplement creatine protects against traumatic brain injury. Ann. Neurol., 2000, 48, 723-729.
222. Prass, K.; Royl, G.; Lindauer, U.; Freyer, D.; Megow, D.; Dirnagl, U.; Stöckler-Ipsiroglu, G.; Wallimann, T.; Priller, J. Improved reperfusion and neuroprotection by creatine in a mouse model of stroke. J. Cereb. Blood Flow. Metab., 2007, 27, 452-459.
223. Op't Eijnde, B.; Jijakli, H.; Hespel, P.; Malaisse, W.J. Creatine supplementation increases soleus muscle creatine content and lowers the insulinogenic index in an animal model of inherited type 2 diabetes. Int. J. Mol. Med., 2006, 17, 1077-1084.
224. Rodriguez, M.C.; MacDonald, J.R.; Mahoney, D.J.; Parise, G.; Beal, M.F.; Tarnopolsky, M.A. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve, 2007, 35, 235-242.
225. Henchcliffe, C.; Beal, M.F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol., 2008, 4, 600-609.
226. Bender, A.; Koch, W.; Elstner, M.; Schombacher, Y.; Bender, J.; Moeschl, M., Gekeler, F.; Müller-Myhsok, B.; Gasser, T.; Tatsch, K.; Klopstock, T. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology, 2006, 67, 1262-1264.
227. Bender, A.; Samtleben, W.; Elstner, M.; Klopstock, T. Long-term creatine supplementation is safe in aged patients with Parkinson disease. Nutr. Res., 2008, 28, 172-178.
228. NINDS NET-PD Investigators. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin. Neuropharmacol., 2008, 31, 141-150.
229. Browne, S.E. Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Ann. NY Acad. Sci., 2008, 1147, 358-382.
230. Hersch, S.M.; Gevorkian, S.; Marder, K.; Moskowitz, C.; Feigin, A.; Cox, M.; Como, P.; Zimmerman, C.; Lin, M.; Zhang, L.; Ulug, A.M.; Beal, M.F., Matson, W.; Bogdanov, M.; Ebbel, E.; Zaleta, A.; Kaneko, Y.; Jenkins, B.; Hevelone, N.; Zhang, H.; Yu, H.; Schoenfeld, D.; Ferrante, R.; Rosas, H.D. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, 66, 250-252.
231. Verbessem, P.; Lemiere, J.; Eijnde, B.O.; Swinnen, S.; Vanhees, L.; Van Leemputte, M.; Hespel, P.; Dom, R. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology, 2003, 61, 925-930.
232. Gordon, P.H.; Cheung, Y.K.; Levin, B.; Andrews, H.; Doorish, C.; Macarthur, R.B.; Montes, J.; Bednarz, K.; Florence, J.; Rowin, J.; Boylan, K.; Mozaffar, T.; Tandan, R.; Mitsumoto, H.; Kelvin, E.A.; Chapin, J.; Bedlack, R.; Rivner, M.; McCluskey, L.F.; Pestronk, A.; Graves, M.; Sorenson, E.J.; Barohn, R.J.; Belsh, J.M.; Lou, J.S.; Levine, T.; Saperstein, D.; Miller, R.G.; Scelsa, S.N. Combination Drug Selection Trial Study Group. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph. Lateral Scler., 2008, 9, 212-222.
233. Shefner, J.M.; Cudkowicz, M.E.; Schoenfeld, D.; Conrad, T.; Taft, J.; Chilton, M.; Urbinelli, L.; Qureshi, M.; Zhang, H.; Pestronk, A.; Caress, J.; Donofrio, P.; Sorenson, E.; Bradley, W.; Lomen-Hoerth, C.; Pioro, E.; Rezania, K.; Ross, M.; Pascuzzi, R.; Heiman-Patterson, T.; Tandan, R.; Mitsumoto, H.; Rothstein, J.; Smith-Palmer, T.; MacDonald, D.; Burke, D.; NEALS Consortium. A clinical trial of creatine in ALS. Neurology, 2004, 63, 1656-1661.
234. Balkis Budin, S.; Othman, F.; Louis, S.R.; Abu Bakar, M.; Radzi, M.; Osman, K.; Das, S.; Mohamed, J. Effect of alpha lipoic acid on oxidative stress and vascular wall of diabetic rats. Rom. J. Morphol. Embryol., 2009, 50, 23-30.
235. Johnsen-Soriano, S.; Garcia-Pous, M.; Arnal, E.; Sancho-Tello, M.; Garcia-Delpech, S.; Miranda, M.; Bosch-Morell, F.; Diaz-Llopis, M.; Navea, A.; Romero, F.J. Early lipoic acid intake protects retina of diabetic mice. Free Radic. Res., 2008, 42, 613-617.
236. Bureković, A.; Terzić, M.; Alajbegović, S.; Vukojević, Z.; Hadzić, N. The role of alpha-lipoic acid in diabetic polyneuropathy treatment. Bosn. J. Basic. Med. Sci., 2008, 8, 341-345.
237. Shen, W.; Hao, J.; Tian, C.; Ren, J.; Yang, L.; Li, X.; Luo, C.; Cotma, C.W.; Liu, J. A combination of nutriments improves mitochondrial biogenesis and function in skeletal muscle of type 2 diabetic Goto-Kakizaki rats. PLoS ONE, 2008, 3, e2328.
238. Xiang, G.D.; Sun, H.L.; Zhao, L.S.; Hou, J.; Yue, L.; Xu, L. The antioxidant alpha-lipoic acid improves endothelial dysfunction induced by acute hyperglycaemia during OGTT in impaired glucose tolerance. Clin. Endocrinol. (Oxf), 2008, 68, 716-723.
239. Hager, K.; Marahrens, A.; Kenklies, M.; Riederer, P.; Munch, G. β-Lipoic acid as a new treatment option for Alzheimer type dementia. Arch. Gerontol. Geriat., 2001, 32, 275-282.
240. Hager, K.; Kenklies, M.; McAfoose, J.; Engel, J., Münch, G. Alpha-lipoic acid as a new treatment option for Alzheimer's disease - a 48 months follow-up analysis. J. Neural Transm. Suppl., 2007, 72, 189-193.
241. Moreira, P.I.; Harris, P.L.R.; Zhu, X.; Santos, M.S.; Oliveira, C.R.; Smith, M.A.; Perry, G. Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J. Alzheimer Dis., 2007, 12, 195-206.
242. Suh, J.H.; Wang, H.; Liu, R.M.; Liu, J.; Hagen, T.M. (R)-alpha-lipoic acid reverses the age-related loss in GSH redox status in post-mitotic tissues: evidence for increased cysteine requirement for GSH synthesis. Arch. Biochem. Biophys., 2004, 423, 126-135.
243. Andreassen, O.A.; Ferrante, R.J.; Dedeoglu, A.; Beal, M.F. Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport, 2001, 12, 3371-3373.
244. Quinn, J.F.; Bussiere, J.R.; Hammond, R.S.; Montine, T.J.; Henson, E.; Jones, R.E.; Stackman, R.W.; Jr. Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol. Aging, 2007, 28, 213-225.
245. Aliev, G.; Liu, J.; Shenk, J.C.; Fischbach, K.; Pacheco, G.J.; Chen, S.G.; Obrenovich, M.E.; Ward, W.F.; Richardson, A.G.; Smith, M.A.; Gasimov, E.; Perry, G.; Ames, B.N. Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats. J. Cell Mol. Med., 2009, 13, 320-333.
246. Shenk, J.C.; Liu, J.; Fischbach, K.; Xu, K.; Puchowicz, M.; Obrenovich, M.E.; Gasimov, E.; Alvarez, L.M.; Ames, B.N.; Lamanna, J.C.; Aliev, G. The effect of acetyl-L-carnitine and R-alpha-lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease. J. Neurol. Sci., 2009, 283, 199-206.
247. Suchy, J.; Chan, A.; Shea, T.B. Dietary supplementation with a combination of alpha-lipoic acid, acetyl-L-carnitine, glycerophosphocoline, docosahexaenoic acid, and phosphatidylserine reduces oxidative damage to murine brain and improves cognitive performance. Nutr. Res., 2009, 29, 70-74.
248. Chan, A.; Shea, T.B. Effects of dietary supplementation with N-acetyl cysteine, acetyl-L-carnitine and S-adenosyl methionine on cognitive performance and aggression in normal mice and mice expressing human ApoE4. Neuromol. Med., 2007, 9, 64-69.
249. Chan, A.; Paskavitz, J.; Remington, R.; Rasmussen, S.; Shea, T.B. Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension. Am. J. Alzheimers Dis. Other Dement., 2009, 23, 571-85.
250. Remington, R.; Chan, A.; Paskavitz, J.; Shea, T.B. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study. Am. J. Alzheimers Dis. Other Dement., 2009, 24, 27-33.
251. Bianchetti, A.; Rozzini, R.; Trabucchi, M. Effects of acetyl-Lcarnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Curr. Med. Res. Opin., 2003, 19, 350-353.
252. Montgomery, S.A.; Thal, L.J.; Amrein, R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int. Clin. Psychopharmacol., 2003, 18, 61-71.
253. Hudson, S.; Tabet, N. Acetyl-L-carnitine for dementia. Cochrane Database Syst. Rev., 2003, 2, CD003158.
254. Yang, X.; Yang, Y.; Li, G.; Wang, J.; Yang, E.S. Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. J. Mol. Neurosci., 2008, 34, 165-171.
255. Sena, C,M.; Nunes, E.; Gomes, A.; Santos, M.S.; Proença, T.; Martins, M.I.; Seiça, R.M. Supplementation of coenzyme Q10 and alpha-tocopherol lowers glycated hemoglobin level and lipid peroxidation in pancreas of diabetic rats. Nutr. Res., 2008, 28, 113-121.
256. Tsuneki, H.; Sekizaki, N.; Suzuki, T.; Kobayashi, S.; Wada, T.; Okamoto, T.; Kimura, I.; Sasaoka, T. Coenzyme Q10 prevents high glucose-induced oxidative stress in human umbilical vein endothelial cells. Eur. J. Pharmacol., 2007, 566, 1-10.
257. Modi, K.; Santani, D.D.; Goyal, R.K.; Bhatt, P.A. Effect of coenzyme Q10 on catalase activity and other antioxidant parameters in streptozotocin-induced diabetic rats. Biol. Trace Elem. Res., 2006, 109, 25-34.
258. Murphy, M.P.; Smith, R.A. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv. Drug Deliv. Rev., 2000, 41, 235-250.
259. Smith, R.A.; Porteous, C.M.; Gane, A.M.; Murphy, M.P. Delivery of bioactive molecules to mitochondria in vivo. Proc. Natl. Acad. Sci. USA, 2003, 100, 5407-5412.
260. Smith, R.A.; Porteous, C.M.; Coulter, C.V.; Murphy, M.P. Selective targeting of an antioxidant to mitochondria. Eur. J. Biochem., 1999, 263, 709-716.
261. Jauslin, M.L.; Meier, T.; Smith, R.A.; Murphy, M.P. Mitochondria targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J., 2003, 17, 1972-1974.
262. Siler-Marsiglio, K.I.; Pan, Q.; Paiva, M.; Madorsky, I.; Khurana, N.C.; Heaton, M.B. Mitochondrially targeted vitamin E and vitamin E mitigate ethanol-mediated effects on cerebellar granule cell antioxidant defense systems. Brain Res., 2005, 1052, 202-211.
263. Ernster, L.; Forsmark, P.; Nordenbrand, K. The mode of action of lipid-soluble antioxidants in biological membranes: relationship between the effects of ubiquinol and vitamin E as inhibitors of lipid peroxidation in submitochondrial particles. Biofactors, 1992, 3, 241-248.
264. Hwang, P.M.; Bunz, F.; Yu, J.; Rago, C.; Chan, T.A.; Murphy, M.P.; Kelso, G.F.; Smith, R.A.; Kinzler, K.W.; Vogelstein, B. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat. Med., 2001, 7, 1111-1117.
265. Bedogni, B.; Pani, G.; Colavitti, R.; Riccio, A.; Borrello, S.; Murphy, M.; Smith, R.; Eboli, M.L.; Galeotti, T. Redox regulation of cAMPresponsive element-binding protein and induction of manganous superoxide dismutase in nerve growth factor-dependent cell survival. J. Biol. Chem., 2003, 278, 16510-16519.
266. Dhanasekaran, A.; Kotamraju, S.; Kalivendi, S.V.; Matsunaga, T.; Shang, T.; Keszler, A.; Joseph, J.; Kalyanaramank B. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J. Biol. Chem., 2004, 279, 37575-37587.
267. Lu, C.; Zhang, D.; Whiteman, M.; Armstrong, J.S. Is antioxidant potential of the mitochondrial targeted ubiquinone derivative MitoQ conserved in cells lacking mtDNA? Antioxid. Redox Signal., 2008, 10, 651-660.
268. Reddy, P.H. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J. Biomed. Biotechnol., 2006, 3, 31372.
269. Szeto, H.H. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J., 2006, 8, E521-E531.
270. Zhao, K.; Luo, G.; Zhao, G.M.; Schiller, P.W.; Szeto, H.H. Transcellular transport of a highly polar 3+ net charge opioid tetrapeptide. J. Pharmacol. Exp. Ther., 2003, 304, 425-432.
271. Zhao, K.; Zhao, G.M.; Wu, D.; Soong, Y.; Birk, A.V.; Schiller, P.W.; Szeto, H.H. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J. Biol. Chem., 2004, 279, 34682-34690.
272. Szeto, H.H. Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury. Antioxid. Redox Signal., 2008, 10, 601-619.
273. Zhao; K.; Luo, G.; Giannelli, S.; Szeto, H.H. Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochem. Pharmacol., 2005, 70, 1796-1806.
274. Petri, S.; Kiaei, M.; Damiano, M.; Hiller, A.; Wille, E.; Manfredi, G.; Calingasan, N.Y.; Szeto, H.H.; Beal, M.F. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J. Neurochem., 2006, 98, 1141-1148.
275. Yang, L.; Zhao, K.; Calingasan, N.Y.; Luo, G.; Szeto, H.H.; Beal, F. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Antioxid. Redox Signal., 2009, [Epub ahead of print].
276. Thomas, D.A.; Stauffer, C.; Zhao, K.; Yang, H.; Sharma, V.K.; Szeto, H.H.; Suthanthiran, M. Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves post-transplantation function. J. Am. Soc. Nephrol., 2007, 18, 213-222.